규제 업데이트

The Korean Pharmaceutical Association rejected the remote‑medicine industry's claim that 23.4% of patients missed medication due to delivery limits, citing official health‑insurance data showing dispensing rates of 95.6% in June 2023 and 92.1% in Dec 2025.

The National Health Insurance Labor Union criticized the government's decision to keep the 2027 health insurance contribution rate unchanged, warning it could accelerate financial deterioration amid rising medical demand.

Ajou Pharmaceutical, together with G.L. PharmTech, secured MFDS approval for Latica Eye Drops 5% (recopolabone hydrate, code AJU‑S56), marking the company’s first marketed new drug and Korea’s 44th domestically developed new drug for dry eye.

Government promotion of the 실손24 electronic claim service has seen limited uptake, with only 13% of indemnity insurance holders enrolled as of July 2026.

The Ministry of Health and Welfare approved a pilot to cut the health‑insurance listing window for rare disease treatments from 240 days to up to 100 days and simplify reimbursement procedures.

Lawmakers propose amendments to the Health Care Personnel Support Act, Medical Service Act, and Nursing Act to strengthen protection against workplace bullying in medical institutions.

The Ministry of Health and Welfare confirmed the 2027 health insurance premium rate will remain at 7.19% for both employee and regional subscribers, keeping the property premium score at 211.5 won.

The Korea Pharmaceutical Bio Association and the Ministry of Food and Drug Safety will host a technical training on parametric release for final sterilized product manufacturers on September 29 in Cheongju.

The National Assembly has filed two bills—one amending the Health‑Medical Technology Promotion Act and another proposing a regulatory sandbox—to accelerate validation and commercialization of new health‑care technologies.

The Ministry of Health and Welfare announced that a State Council‑approved amendment to the National Health Insurance Act now clearly defines reimbursable and non‑reimbursable drugs, while preserving protections for severe and rare disease patients.

The Cheongju City Pharmacists Association convened a meeting on Sep 7 to discuss recent regional pharmacy issues and challenges of non-face-to-face drug delivery, focusing on warehouse-type pharmacies.

Labor unions urged the government to promptly apply the statutory 20% national treasury support and devise financial measures to strengthen health insurance coverage.